Patent Assignment
Reel/Frame 057998/0974
Assignment of Assignor's Interest
Recorded: 2021-11-02
Pages: 7
Assignors
DEQUEANT, MARY-LEE
Executed: 2021-10-13
KALAITZIDIS, DEMETRIOS
Executed: 2021-10-27
GHONIME, MOHAMMED
Executed: 2021-10-14
Assignee
CRISPR THERAPEUTICS AG
BAARERSTRASSE 14, ZUG, 6300, SWITZERLAND
Covered Properties
(4)
Genetically Engineered T Cells with Regnase-1 and/or Tgfbrii Disruption Have Improved Functionality and Persistence
Application:
17/483,100 →
Publication:
US 2022/0090012
Genetically Engineered T Cells with Regnase-1 and/or Tgfbrii Disruption Have Improved Functionality and Persistence
Genetically Engineered T Cells with Regnase-1 and/or Tgfbrii Disruption Have Improved Functionality and Persistence
Genetically Engineered T Cells with Regnase-1 and/or Tgfbrii Disruption Have Improved Functionality and Persistence